Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance, or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Irfan Tamboli (Head of Sales) – Market Insights Reports, Phone: + 1704 266 3234 | +91-750-707-8687, sales@marketinsightsreports.com | irfan@marketinsightsreports.com. Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CB-010, an off-the-shelf allogeneic anti-CD19, genome-edited CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma (B-NHL). Rachel Haurwitz, Ph.D., President and CEO of Caribou, stated, “We are pleased with the outcome and look forward to negotiating a reasonable license fee with Intellia. Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, today announced that co-founder Jennifer Doudna, Ph.D., has been awarded the 2020 Nobel Prize in Chemistry. “Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc. About ProMab Biotechnologies, Inc. news. “We could not be more excited to see Jennifer’s groundbreaking work and accomplishments recognized by the Nobel Prize,” said Rachel Haurwitz, Ph.D., President and CEO of Caribou Biosciences. Please contact our sales professional (sales@marketinsightsreports.com), we will ensure you obtain the report which works for your needs. © 2020 Caribou Biosciences, Inc. All rights reserved. This CRISPR & Cas Genes Market statistical surveying report underlines the leading merchants in this market everywhere throughout the world. Get Exclusive Sample Copy of the Report to understand the structure of the complete report: https://www.marketinsightsreports.com/reports/08262254869/global-crispr-cas-genes-market-size-status-and-forecast-2020-2026/inquiry?mode=69, Top Key Players in the Global CRISPR & Cas Genes Market:CRISPR Therapeutics AG(NAS: CRSP), AstraZeneca Plc(OTC: AZNCF), Addgene, Caribou Biosciences, Inc., Cellectis, Editas Medicine, Inc., Egenesis, Hoffmann-La Roche Ltd., Horizon Discovery Group Plc, Genscrip, Danaher Corporation(NYS: DHR), Intellia Therapeutics, Inc.(NAS: NTLA), Lonza, Merck KGaA, New England BioLabs, Takara Bio, Inc., Synthego, Mammoth Biosciences, Inscripta, Inc., Cibus. Additionally, Caribou offers licenses to its CRISPR-Cas9 foundational IP in multiple fields including research tools, internal research use, diagnostics, and industrial biotechnology. BERKELEY, CA – September 26, 2019 –  On September 19, 2019, a three-member JAMS panel issued an Interim Award in the arbitration between Intellia Therapeutics, Inc. (Intellia) and Caribou Biosciences, Inc. (Caribou). Therefore, the initiative is expected to encourage other players to take advantage of this crisis and launch new products. The company is developing an internal pipeline of off-the-shelf CAR-T cell therapies, other gene-edited cell therapies, and engineered gut microbes. Interested companies may contact Caribou at licensing@cariboubio.com. Thus far, research efforts to identify new CRISPR-Cas systems have largely focused on those containing single-protein effectors based on the underlying assumption that such systems will ultimately be easier to deliver to eukaryotic cells. Caribou has granted patents and pending patent applications on the FokI-Cascade system and on Cas3-Cascade. “CB-010 is distinct among allogeneic CAR-Ts since the critical checkpoint PD-1 is eliminated to reduce CAR-T cell exhaustion, which we believe offers a crucial therapeutic advantage.”. We develop technology-based solutions for cellular engineering and analysis based on the CRISPR-Cas9 technology platform. Caribou’s proprietary technologies put the company at the forefront of creating new medical therapies. Influence of the CRISPR & Cas Genes Market report: -Comprehensive assessment of all opportunities and risks in the CRISPR & Cas Genes Market. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request, and Market development rate, and figure and so on. For more information about Caribou visit www.cariboubio.com and follow the Company @CaribouBio. -Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale. -Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. "We are extremely proud of the research conducted by our team, as these findings have the potential to serve as a key roadmap for repurposing alternative, previously untapped multi-protein CRISPR-Cas systems for biotechnology applications,” said Steven Kanner, Ph.D., Caribou’s Chief Scientific Officer. Under the Interim Award, the panel awarded to Caribou “the exclusive, perpetual, worldwide right to develop and commercialize” the Cas9 chRDNA technology in the field of human therapeutics and declared this right “created on the day Caribou began to treat the chRDNA technology as a human therapeutic.” This right is “subject to a reasonable license fee, which the parties shall negotiate separately.” The panel also determined that, subject to the above right to Caribou, the disputed technologies are otherwise within the scope of the license granted by Caribou to Intellia in 2014. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. “We are excited for the opportunity to have access to this highly advanced, humanized molecule and believe it will significantly advance our promising CB-011 CAR-T program,” said Steven Kanner, PhD, Chief Scientific Officer of Caribou. 617-761-6724, Caribou Biosciences, Inc. Caribou Biosciences, Inc. provides medical therapies and bio-based products.